FDA approves Eli Lilly's once-weekly insulin pen, setting up rivalry with Novo
RegulatoryapprovedOnswikPositive
AI Analysis
Summary
The FDA has approved Eli Lilly's Onswik, a once-weekly basal insulin injection for type 2 diabetes patients, positioning the company to compete with Novo in the long-acting insulin market.
Outcome Details
FDA approval of once-weekly basal insulin injection
Importance:8/10
Sentiment:
0.80
FDA approvaldiabetesinsulinEli Lillyonce-weekly formulationbasal insulin
Related Companies
Read the original article
Published by Endpoints News on September 24, 2026 4:16 PM